Notice of Iran-related Disclosure Filed Pursuant to Section 13(r)(3) of the Exchange Act (irannotice)
February 02 2022 - 7:35AM
Edgar (US Regulatory)
Novartis AG
PO Box
CH 4002 Basel
US Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
February 2, 2022
Re: Notice of disclosure filed in Exchange Act Annual Report under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act
Ladies and Gentlemen:
Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as amended, notice is hereby provided that Novartis AG has made disclosure pursuant to those provisions in its Annual Report on Form 20-F for the year ended December 31, 2021, which was filed with the Securities and Exchange Commission on February 2, 2022.
Respectfully submitted,
Novartis AG
/s/ KAREN L. HALE
|
/s/ HARRY KIRSCH
|
Karen L. Hale
|
Harry Kirsch
|
Chief Legal Officer
|
Chief Financial Officer
|
of Novartis
|
of Novartis
|
Novartis (NYSE:NVS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Sep 2023 to Sep 2024